Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.
The objective of this study was to determine the distribution profile of the novel endotoxin antagonist E5564 in plasma obtained from fasted human subjects with various lipid concentrations. Radiolabeled E5564 at 1 microM was incubated in fasted plasma from seven human subjects with various total cholesterol (TC) and triglyceride (TG) concentrations for 0.5 to 6 h at 37 degrees C. Following these incubations, plasma samples were separated into their lipoprotein and lipoprotein-deficient fractions by ultracentrifugation and were assayed for E5564 radioactivity. TC, TG, and protein concentrations in each fraction were determined by enzymatic assays. Lipoprotein surface charge within control and phosphatidylinositol-treated plasma and E5564's influence on cholesteryl ester transfer protein (CETP) transfer activity were also determined. We observed that the majority of E5564 was recovered in the high-density lipoprotein (HDL) fraction. We further observed that incubation in plasma with increased levels of TG-rich lipoprotein (TRL) lipid (TC and TG) concentrations resulted in a significant increase in the percentage of E5564 recovered in the TRL fraction. In further experiments, E5564 was preincubated in human TRL. Then, these mixtures were incubated in hypolipidemic human plasma for 0.5 and 6 h at 37 degrees C. Preincubation of E5564 in purified TRL prior to incubation in human plasma resulted in a significant decrease in the percentage of drug recovered in the HDL fraction and an increase in the percentage of drug recovered in the TRL and low-density lipoprotein fractions. These findings suggest that the majority of the drug binds to HDLs. Preincubation of E5564 in TRL prior to incubation in normolipidemic plasma significantly decreased the percentage of drug recovered in the HDL fraction. Modifications to the lipoprotein negative charge did not alter the E5564 concentration in the HDL fraction. In addition, E5564 does not influence CETP-mediated transfer activity. Information from these studies could be used to help identify the possible components of lipoproteins which influence the interaction of E5564 with specific lipoprotein particles.
Wasan
Kishor M
KM
Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada. Kwason@interchange.ubc.ca
Sivak
Olena
O
Cote
Richard A
RA
MacInnes
Aaron I
AI
Boulanger
Kathy D
KD
Lynn
Melvyn
M
Christ
William J
WJ
Hawkins
Lynn D
LD
Rossignol
Daniel P
DP
D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D053480:Cholesterol Ester Transfer Proteins; D004731:Endotoxins / Q000037:antagonists & inhibitors*; D006023:Glycoproteins; D006801:Humans; D008050:Lipid A / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008077:Lipoproteins, LDL / Q000378:metabolism*; D011485:Protein Binding; D011817:Rabbits; D014018:Tissue Distribution; D014280:Triglycerides / Q000378:metabolism*
C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; C404742:E5564; D004731:Endotoxins; D006023:Glycoproteins; D008050:Lipid A; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D014280:Triglycerides; D002784:Cholesterol